Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath of nerve fibers. MSC cell therapies represent a promising approach to MS treatment through dual action: immunomodulation and neuroprotection.

MSC cells can inhibit the autoimmune attack on myelin by modulating T-cells, B-cells, and dendritic cells. Additionally, MSC cells secrete neurotrophic factors that support neuron survival and promote remyelination. Phase I/II clinical studies have demonstrated the safety and potential efficacy of MSC therapy in relapsing-remitting and primary progressive MS.

GaiaCell is developing intravenous and intrathecal MSC preparations for multiple sclerosis treatment. Our approach is based on personalized medicine, where we tailor the treatment protocol to each patient's MS stage and type.